New Classification of Rheumatoid Arthritis Based on Immune Cells and Clinical Characteristics
Jiaqian Wang,Yuan Xue,Liang Zhou
DOI: https://doi.org/10.2147/jir.s395566
IF: 4.5
2024-05-23
Journal of Inflammation Research
Abstract:Jiaqian Wang, 1 Yuan Xue, 2 Liang Zhou 3 1 Department of Orthopaedic, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 2 Department of Orthopaedic, Wuxi Ninth People's Hospital of Soochow University, Wuxi, 214000, People's Republic of China; 3 Department of Orthopaedic, Lianshui County People's Hospital, Huai'an, People's Republic of China Correspondence: Jiaqian Wang, Email Background: Rheumatoid arthritis (RA) is a chronic systemic immune disease characterized by joint synovitis, but there are differences in clinical manifestations and serum test results among different patients. Methods: This is a bioinformatics study. We first obtained the gene expression profile of RA and normal synovium from the database, and screened the differentially expressed immune related genes for enrichment analysis. Subsequently, we classified RA into three subtypes by unsupervised clustering of serum gene expression profiles based on immune enrichment scores. Then, the enrichment and clinical characteristics of different subtypes were analyzed. Finally, according to the infiltration of different subtypes of immune cells, diagnostic markers were screened and verified by qRT-PCR. Results: C1 subtype is related to the increase of neutrophils, C-reactive protein and erythrocyte sedimentation rate, and joint pain is more significant in patients. C2 subtype is related to the expression of CD8+T cells and Tregs, and patients have mild joint pain symptoms. The RF value of C3 subtype is higher, and the expression of various immune cells is increased. CD4 T cells, NK cells activated, macrophages M1 and neutrophils are immune cells significantly infiltrated in synovium and serum of RA patients. IFNGR1, TRAC, IFITM1 can be used as diagnostic markers of different subtypes. Conclusion: In this study, RA patients were divided into different immune molecular subtypes based on gene expression profile, and immune diagnostic markers were screened, which provided a new idea for the diagnosis and treatment of RA. Keywords: rheumatoid arthritis, molecular subtype, immune cells, immunodiagnostic markers Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by joint synovitis. Persistent synovitis can lead to irreversible damage of intra-articular cartilage and bone, joint dysfunction, and even disability. 1 The Global Burden of Disease research report showed that the prevalence of RA increased by 7.4% and the incidence rate increased by 8.2% between 1990 and 2017. 2 However, the exact cause of RA has not yet been clarified, environmental, infectious, genetic and other factors are closely related. 3 Among them, it is widely recognized that immune factors play a crucial role in the whole process. 4 Studies have shown that the infiltration of immune cells in synovium seriously affects the occurrence and progression of RA. 5 For example, macrophages can secrete a large number of cytokines, chemokines and degrading enzymes, which are positively correlated with the severity of the disease. 6 Activated CD4+T cells can initiate specific immune responses, leading to joint inflammation and bone destruction. 7 Other immune cells, such as natural killer cells, also play a regulatory role in RA. 8 Therefore, it is very important to evaluate the infiltration of immune cells in synovium and determine the differences of immune cell components in order to clarify the pathogenesis of RA. In addition, although the basic pathological change of RA is synovitis, some patients show alternate onset and relief of joint pain, while others show persistent swelling and joint pain, with almost no relief process. 9 Even some patients have extra-articular manifestations, with 14.7% of patients developing interstitial lung disease. 10 Therefore, early diagnosis and classification of RA is of great significance for the treatment of RA. 11 However, the current role of serological diagnostic markers is limited. Even if rheumatoid factor and anti-cyclic citrulline antibody are positive, RA cannot be diagnosed, and it still needs to be based on long-term clinical symptoms. 12 C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) increased in the acute stage of RA, but there was no specificity. 13 This brings great difficulties to the early diagnosis of RA, but the first change in RA patients is usually at the molecular level. 14 With the development and widespread use of microarray and high-throughput sequencing technology, we can early identify changes in gene expression and screen out immune diagnostic markers. 15 Fo -Abstract Truncated-
immunology